Delcath Systems, Inc. ( (DCTH) ) has released its Q2 earnings. Here is a breakdown of the information Delcath Systems, Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Delcath Systems, Inc. is an interventional oncology company specializing in the treatment of primary and metastatic liver cancers, utilizing its proprietary HEPZATO KIT and CHEMOSAT systems to deliver high-dose chemotherapy directly to the liver while minimizing systemic exposure.
In its second quarter of 2025, Delcath Systems reported a significant increase in total revenue, reaching $24.2 million compared to $7.8 million in the same period of 2024. The company also achieved a net income of $2.7 million, a notable improvement from the net loss of $13.7 million in the previous year.
Key financial highlights for the quarter include a substantial rise in HEPZATO KIT revenue to $22.5 million and CHEMOSAT revenue to $1.7 million. Delcath also reported an impressive gross margin of 86% and a positive adjusted EBITDA of $9.8 million. Additionally, the company activated three new U.S. centers, bringing the total to 20 active centers, and announced plans to expand patient access through a Medicaid National Drug Rebate Agreement.
Looking ahead, Delcath Systems has updated its financial guidance for 2025, projecting total revenue from CHEMOSAT and HEPZATO KIT to be between $93 to $96 million, with gross margins expected to range from 83% to 85%. The company anticipates positive adjusted EBITDA and cash flow in each quarter of the year.
With a strong financial performance and strategic initiatives in place, Delcath Systems is well-positioned to pursue further growth opportunities and expand the use of its HEPZATO KIT in treating liver cancers, as highlighted by the company’s management.